Background: Human cancer cell lines grown in the presence of the cytotoxic agent mitoxantrone frequently develop resistance associated with a reduction in intracellular drug accumulation without increased expression of the known drug resistance transporters P-glycoprotein and multidrug resistance protein (also known as multidrug resistanceassociated protein). Breast cancer resistance protein (BCRP) is a recently described adenosine triphosphate-binding cassette transporter associated with resistance to mitoxantrone and anthracyclines. This study was undertaken to test the prevalence of BCRP overexpression in cell lines selected for growth in the presence of mitoxantrone. Methods: Total cellular RNA or poly A + RNA and genomic DNA were isolated from parental and drug-selected cell lines. Expression of BCRP messenger RNA (mRNA) and amplification of the BCRP gene were analyzed by northern and Southern blot hybridization, respectively. Results: A variety of drugresistant human cancer cell lines derived by selection with mitoxantrone markedly overexpressed BCRP mRNA; these cell lines included sublines of human breast carcinoma (MCF-7), colon carcinoma (S1 and HT29), gastric carcinoma (EPG85-257), fibrosarcoma (EPF86-079), and myeloma (8226) origins. Analysis of genomic DNA from BCRPoverexpressing MCF-7/MX cells demonstrated that the BCRP gene was also amplified in these cells. Conclusions: Overexpression of BCRP mRNA is frequently observed in multidrug-resistant cell lines selected with mitoxantrone, suggesting that BCRP is likely to be a major cellular defense mechanism elicited in response to exposure to this drug. It is likely that BCRP is the putative "mitoxantrone transporter" hypothesized to be present in these cell lines. [J Natl Cancer Inst 1999;91:429-33] Transport-mediated resistance to anticancer drugs has been a subject of active investigation for a number of years. Currently, two members of the adenosine triphosphate (ATP)-binding cassette (ABC) superfamily of transport proteins, P-glycoprotein (Pgp) and multidrug resistance protein (MRP; also known as multidrug resistance-associated protein), are known to cause cultured tumor cell lines to become resistant to multiple anticancer drugs (1, 2) . However, when the drug mitoxantrone is used as the selecting agent, the resulting drug-resistant cell lines frequently do not overexpress Pgp or MRP, despite a demonstrable reduction in drug accumulation (3) (4) (5) (6) (7) (8) . This result suggests that a novel transport-mediated drug resistance mechanism(s) is recruited in response to selection with mitoxantrone. The unique mitoxantrone-selected phenotype is characterized by the following: resistance to mitoxantrone, doxorubicin, and daunorubicin; an ATP-dependent reduction in drug accumulation; and sensitivity to vinca alkaloids, paclitaxel, and cisplatin. The drug resistance phenotype typically associated with mitoxantrone selection has also been observed in human breast carcinoma MCF-7/AdrVp cells, which were not selected with mitoxantrone but were selected with doxorubicin in the presence of verapamil, an inhibitor of Pgp (9) . Despite the method of selection, MCF-7/AdrVp cells are considerably more resistant to mitoxantrone than to doxorubicin (10) .
Recently, MCF-7/AdrVp cells were found to overexpress a novel ABC transport protein designated breast cancer resistance protein, or BCRP (11) . Transfection of BCRP complementary DNA (cDNA) into drug-sensitive MCF-7 cells conferred resistance to mitoxantrone, daunorubicin, and doxorubicin but not to vinca alkaloids, paclitaxel, or cisplatin. In addition, lower intracellular accumulation and retention of daunorubicin and an ATP-dependent enhancement of the efflux of rhodamine 123 were observed in the transfected cells (11) . Hence, transfection with BCRP cDNA reproduced in MCF-7 cells the drug resistance phenotype typical of mitoxantrone-selected cell lines. This finding suggests that BCRP may be responsible for the novel transport mechanism observed in the mitoxantrone-selected cell lines. This study was undertaken to test the prevalence of BCRP overexpression in mitoxantrone-selected cell lines.
MATERIALS AND METHODS
Cell lines. The cell lines used and the conditions under which they were cultured are given in Table 1 and references listed therein. The S1M1-3.2 colon carcinoma cells were derived from S1 cells (a subclone of human colon carcinoma cell line LS174T) by selection for growth in increasing concentrations of mitoxantrone until a final concentration of 3.2 M was achieved. The HL-60/ MX2 leukemia cells were purchased from the American Type Culture Collection (Manassas, VA) and were maintained in culture as described previously (12) .
Northern blot hybridization. Total cellular RNA was used for northern blot hybridization analysis in all cases except for H209 or H69 cells, where poly A + RNA was used. RNA extraction and northern blotting were performed by standard techniques as described previously (11) . A 795-base-pair (bp) fragment of the 3Ј end of the 2418-bp BCRP cDNA (GenBank database accession number AF098951) was used as the hybridization probe after labeling with [ 32 P]deoxycytidine triphosphate ("Prime-a-Gene" labeling kit; Promega Corp., Madison, WI) as described previously (11) . To control for variations in sample loading, the blots were stripped, then rehybridized with 32 P-labeled ␤-actin or 18S RNA probes as described previously (11) . The levels of messenger RNA (mRNA) expression in different cell lines were compared by an arbitrary grading system (Table 1 ) based on visual determination of signal intensities.
Southern blot hybridization. Genomic DNA was isolated from the MCF-7 cell lines, digested with EcoRI or BamHI, and separated by 0.8% agarose gel electrophoresis. After staining with ethidium bromide, the DNA was transferred and fixed to a nitrocellulose filter by use of standard techniques (13) . The filter was hybridized with the 32 P-labeled 795-bp BCRP probe described above for northern blot analysis.
Northern or Southern blots were prepared by collaborating authors (S. P. C. 
RESULTS
The drug-resistant cell lines used and their characteristics with respect to the degree of resistance that they exhibit and expression (relative to parental cells) of mRNAs encoding the multidrug resistance transporters Pgp, MRP, and BCRP are summarized in Table 1 .
All of the mitoxantrone-selected sublines derived from human breast carcinoma MCF-7 cells overexpressed BCRP mRNA relative to its expression in parental MCF-7 cells. BCRPpositive cell lines included MCF-7/Mitox cells (3) (Fig. 1, A (Fig. 1, B; lanes 4-6) . The MCF-7/MX cells ( Fig. 1, B ; lanes 4-6) appeared to express amounts of BCRP mRNA comparable to or greater than those expressed by the MCF-7/AdrVp1000 cells ( Fig. 1, B Fig. 1, B ; Table 1 ). Mitoxantrone-selected human breast carcinoma MDA-MB-231RNOV cells, which are less resistant to mitoxantrone than the MCF-7 sublines, demonstrated only slightly elevated levels of BCRP mRNA compared with the levels seen in the parental cell line ( Fig. 1, C; lanes 3 and 4) . Amplification of the BCRP gene was detected in MCF-7/ MX PR cells ( Fig. 2; lanes 2 and 8) , MCF-7/MX RS250 cells ( Fig.  2; lanes 3 and 9) , and MCF-7/MX RS600 cells ( Fig. 2; lanes 4 and  10) . No BCRP gene amplification was observed in etoposideselected, MRP-overexpressing MCF-7/VP cells ( Fig. 2 ; lanes 5 and 11) or in methotrexate-selected, DHFR-amplified MCF-7/ MTX cells ( Fig. 2; lanes 6 and 12) .
Human myeloma 8226/MR20 cells are capable of sustained growth in 200 nM mitoxantrone (4) and also demonstrated overexpression of BCRP compared with BCRP expression in parental 8226 cells ( Fig. 1, A; lanes 3 and 4) . The expression of BCRP mRNA in 8226/MR20 cells was less than the amount of BCRP mRNA expressed in MCF-7/Mitox cells ( Fig. 1, A; lane 2) ; however, this may be because the latter cell line is more resistant to mitoxantrone (1208-fold, Table 1 ) than is the former (36-fold, Table 1 ).
Overexpression of BCRP mRNA was also observed in human colon carcinoma S1/M1-3.2 cells (resistant to 3.2 M mitoxantrone) ( Fig. 1, B ; lane 1), compared with parental S1 cells ( Fig.  1, B ; lane 2). Another human colon carcinoma cell line selected with mitoxantrone, HT29RNOV, displayed overexpression of BCRP compared with the BCRP expression in parental HT29 cells ( Fig. 1, C; lanes 1 and 2) .
None of the small-cell lung cancer cell lines tested overexpressed BCRP (data not shown), including those selected with mitoxantrone (H209/MX2 and H209/MX4) ( Table 1) . It is of note that these mitoxantrone-selected lines showed only a low degree of resistance to the drug and also have no demonstrable overexpression of Pgp or MRP. Etoposide-selected H209/V6 cells appear to derive their resistance from a mutated topoisomerase II (16); H69/AR cells, selected with doxorubicin, markedly overexpress MRP (17) .
The human gastric carcinoma-derived resistant EPG85-257RNOV cell line was developed by stepwise selection with mitoxantrone (8) . Compared with parental cells, EPG85-257RNOV cells have no detectable overexpression of Pgp or MRP; they display decreased mitoxantrone accumulation and cross-resistance to anthracyclines, but they retain sensitivity to cisplatin and vinca alkaloids (8, 18) . Northern blot analysis indicated elevated levels of BCRP mRNA in EPG85-257RNOV cells compared with the levels in the parental EPG85-257 cells ( Fig. 1, C; lanes 7 and 8) . In contrast, a Pgp-overexpressing subline selected with daunorubicin, EPG85-257RDB, did not overexpress BCRP relative to its expression in parental EPG85-257 cells ( Fig. 1, C; lane 9) .
BCRP mRNA was not overexpressed in human pancreatic carcinoma EPP85-181 cells selected in mitoxantrone (EPP85-181RNOV) or daunorubicin (EPP85-181RDB) (19) (Fig. 1, C;  lanes 10-12) . The baseline expression of BCRP in the parental EPP85-181 pancreatic carcinoma cells appeared to be lower than that in the parental EPG85-257 gastric carcinoma cells ( Fig. 1,  C; lanes 7 and 10) .
Mitoxantrone-selected EPF86-079RNOV human fibrosarcoma cells displayed overexpression of BCRP mRNA compared with the BCRP mRNA expression in parental EPF86-079 cells ( Fig. 1, C; lanes 5 and 6) .
A mitoxantrone-selected subline of human acute myeloid leukemia HL-60 cells [HL-60/MX2 (12)] did not overexpress 
DISCUSSION
Elevated expression of the novel ABC transporter BCRP is a common feature of many cancer cell lines selected with mitoxantrone and is consistently associated with a phenotype that includes high-level resistance to mitoxantrone, lower resistance to anthracyclines, and sensitivity to vinca alkaloids, paclitaxel, and cisplatin. ATP-dependent export of mitoxantrone, anthracyclines, and rhodamine 123 has been observed in several BCRPpositive, mitoxantrone-resistant cell lines and BCRP-transfected breast cancer cells (7, 11) . Cross-resistance to topoisomerase Idirected agents has been reported in some mitoxantrone-resistant cell lines (20) , but resistance to these agents has not yet been confirmed in BCRP-transfected cells.
The BCRP peptide has the characteristics of a "halftransporter," having only a single ATP-binding domain and a single lipophilic region containing transmembrane domains (11) . Hence, it is possible that the most efficient transmembrane conductance channel contains BCRP as a dimer or multimer either with itself or with another heretofore undescribed "halftransporter" (11) . Although the transfection studies suggest that the enforced overexpression of BCRP cDNA is sufficient to confer drug resistance to the transfected cells (11) , it is possible that another transporter(s) may be involved in a dimeric or a multimeric complex with BCRP, which may contribute to the resistance of the mitoxantrone-selected cell lines. The identification of other transporters that may participate in the BCRP transmembrane conductance channel is currently under active investigation in our laboratory.
The finding of elevated expression of BCRP mRNA in the human colon carcinoma S1M1-3.2 cells suggests that BCRP is the "non-Pgp, non-MRP" drug transporter manifested by this multidrug-resistant cell line. This is of particular importance because of the recent report (7) of a novel and specific inhibitor of the transporter identified in S1M1-3.2 cells. This inhibitor, fumitremorgin C, does not reverse resistance in cells that overexpress Pgp or MRP. In preliminary studies in our laboratory, fumitremorgin C is able to enhance the accumulation and inhibit the efflux of BBR 3390 (an aza-anthrapyrazole drug that is effluxed by BCRP) in BCRP-transfected MCF-7 cells [data not shown; (11) ]. Further development of fumitremorgin C is warranted for use in functional assays of BCRP activity and possibly as a clinical adjunct to chemotherapy, should BCRP protein/ activity levels be shown to be elevated in human cancers.
BCRP expression is associated with multidrug resistance in mitoxantrone-selected cell lines derived from human breast, gastric, and colon cancers, as well as from fibrosarcoma and multiple myeloma cells. High levels of BCRP expression are not associated with strong expression of MRP or Pgp in mitoxantrone-selected cell lines or in multidrug-resistant cell lines known to overexpress MRP or Pgp.
In conclusion, our study indicates that elevated expression of BCRP is frequently observed in mitoxantrone-selected cell lines derived from human multiple myeloma and a number of solid tumors. Considered together with results from BCRP transfection studies (11) , these data demonstrate that BCRP is a novel ABC protein responsible for mediating resistance to mitoxantrone and other important chemotherapeutic agents in a wide variety of human cancer cell lines. 
